Agentic Workflow for Real-Time Pharmacovigilance Signal Triage and Reporting

Manual adverse event (AE) case processing involves repetitive data entry, source verification, and MedDRA coding, taking 45-90 minutes per case. A custom workflow automates ingestion from emails, EMRs, and literature, uses NLP for entity extraction and coding, and auto-populates case forms (CIOMS/MedWatch), cutting handling time to under 15 minutes. This directly reduces FTEs required per case volume and accelerates time-to-initial report.

Traditional signal detection relies on batch processing of aggregated data, creating a lag between event occurrence and pattern recognition. An agentic workflow performs continuous, real-time analysis on incoming AE streams, social media, and scientific literature. Specialized agents correlate events, calculate disproportionality scores (e.g., PRR, ROR), and flag potential signals for review within hours, enabling proactive risk mitigation before issues escalate.

Manual report assembly for regulators (FDA, EMA, PMDA) is error-prone, leading to queries, delays, and compliance risk. A custom workflow enforces data validation rules, ensures consistent MedDRA and WHO-DD coding, and auto-formats reports to E2B(R3) and regional specifications. Every step—from data ingestion to final submission draft—is logged in an immutable audit trail, providing defensible evidence for inspections and reducing audit preparation labor by 60%.

Medical reviewers spend up to 50% of their time on administrative triage and data gathering instead of high-value clinical assessment. The workflow acts as a force multiplier: triage agents classify case seriousness and expectedness, route only validated, complex cases to reviewers with all relevant data (patient history, lab values, similar cases) pre-assembled. This shifts reviewer role from data clerk to strategic decision-maker, improving capacity by 3-4x.

The fully burdened cost of manual AE case processing can exceed $200, driven by labor, systems, and quality control. A custom agentic architecture—integrating with Veeva Safety, Argus, or homegrown systems—automates the costly middle office. The ROI is direct: reducing processing cost to under $50 per case while improving quality and speed. For a company processing 50,000 cases annually, this translates to over $7.5M in annual operational savings.

The business impact is locked in by a scalable, fault-tolerant architecture. The workflow is built on an event-driven pipeline (Apache Kafka), uses orchestration (LangGraph, Prefect) to manage specialized agents for intake, coding, and signal detection, and integrates with core PV systems (Oracle Argus, Veeva) and EMRs (Epic, Cerner). This design handles volume spikes from new drug launches or safety events without adding proportional headcount, turning pharmacovigilance into a variable-cost, scalable operation.

This specialized agent orchestrates the continuous ingestion of adverse event reports from structured databases (e.g., FDA FAERS, EudraVigilance), unstructured sources (medical literature, social media), and internal safety databases. It uses NLP to extract entities (drug, reaction, patient demographics), assess seriousness and expectedness, and perform initial deduplication. The agent validates data quality, routes incomplete cases for enrichment, and assigns a preliminary priority score, transforming fragmented inputs into a structured, queryable case queue.

The core workflow orchestrator manages the validated case pipeline. It routes high-priority or complex cases to a Medical Review Agent that retrieves relevant product information, literature, and historical data to draft a preliminary causality assessment. The orchestrator enforces business rules, manages required review checkpoints (e.g., country-specific requirements), and escalates cases needing human pharmacovigilance expert review via integrated ticketing (ServiceNow, Jira) or directly within a PV system like ARISg or Argus. All agent actions, data retrievals, and rationale are logged to an immutable audit trail.

Upon medical review sign-off, this agent automatically populates the correct regulatory form (CIOMS I, MedWatch 3500A, E2B R3 XML) using the validated case data. It applies jurisdiction-specific formatting rules, calculates timelines (e.g., 15-day vs. periodic reporting), and generates a narrative summary. The agent integrates with document management systems (e.g., Veeva Vault) to fetch templates and store draft outputs, ensuring version control and traceability back to source data. This eliminates manual form-filling, a major source of error and delay.

This governance agent enforces final quality checks before submission. It validates the completed report against regulatory business rules (ICH E2B validation), checks for consistency with the source case, and requires a final authorized sign-off. The agent then routes the approved report to the appropriate submission gateway (e.g., FDA ESG, EMA EVWEB) or to a partner for local submission. It monitors transmission acknowledgements and logs the entire submission lifecycle, creating a defensible audit trail for inspections. Failed transmissions are automatically re-routed or escalated.

The workflow is governed by a central observability layer built on tools like LangSmith or custom Elasticsearch/Kibana stacks. It tracks key metrics: signal volume, triage accuracy, case processing time, agent confidence scores, and submission success rates. This dashboard allows PV operations to monitor throughput, identify bottlenecks (e.g., specific data sources causing quality issues), and retrain NLP models based on expert feedback on agent decisions. It turns the workflow from a static pipeline into a continuously improving operational system.

A production build uses LangGraph or Temporal for core orchestration, with agents built as specialized modules. It integrates via APIs with: Safety Databases (Argus, ARISg), Clinical Data Repos, Document Management (Veeva), and Regulatory Gateways. A vector database (Pinecone, Weaviate) supports rapid retrieval of similar historical cases during review. Deployment is typically containerized (Kubernetes) with strict role-based access controls. The architecture must support phased rollout, starting with triage automation, then moving to full reporting, to manage change and validate agent performance.

The workflow ingests structured and unstructured reports from EHR/EMR systems (e.g., Epic, Cerner), patient support programs, social media listening tools, and regulatory databases (FAERS, EudraVigilance). Agents use NLP to normalize terminology (MedDRA, WHO-DD) and extract key entities (drug, reaction, patient demographics, outcome). This layer replaces manual data entry and aggregation, cutting initial case processing time by up to 60%.

Signal validation requires real-time access to product information management (PIM) systems, drug labeling (SmPC/PI), and clinical trial databases. Agents cross-reference reported events with known side-effect profiles, dosage forms, and lot numbers to assess novelty and causality (using algorithms like Naranjo or WHO-UMC). Integration here prevents false signals and ensures triage logic is grounded in authoritative product data.

Automated draft generation for CIOMS I, MedWatch 3500A, and E2B(R3) XML submissions requires tight integration with document management systems (e.g., Veeva Vault) and regulatory information management (RIM) platforms. Agents populate mandatory fields from the validated case, apply regional formatting rules, and route drafts to the qualified person for pharmacovigilance (QPPV) for review and electronic submission, ensuring compliance with regional timelines (e.g., 15-day expedited reports).

The core orchestration layer, built on frameworks like LangGraph or Camunda, integrates with enterprise case management systems (e.g., ARISg, Argus). It manages state transitions—from Initial Triage to Medical Review to Regulatory Submission—while enforcing SOPs, assigning tasks to medical reviewers, and logging all actions for audit. This replaces fragmented email and spreadsheet tracking, providing a single source of truth for case status.

To support inspections by agencies like the FDA or EMA, every automated decision and data transformation must be logged. The workflow integrates with Quality Management Systems (QMS) and electronic trial master files (eTMF) to automatically capture deviation reports, corrective actions (CAPA), and version-controlled SOPs linked to specific cases. This creates a defensible, inspection-ready record that demonstrates control over the automated process.

Processed cases are streamed to a data warehouse or lakehouse (e.g., Snowflake, Databricks) for longitudinal analysis. This enables disproportionality analysis (e.g., PRR, ROR) and trend detection across the aggregated safety database. The integration allows the workflow to not just process individual reports but also feed back population-level signal insights, closing the loop from case processing to proactive risk management.